

National Stock Exchange of India Circular

Department: Listing	
Download Ref No: NSE/CML/71731	Date: December 10, 2025
Circular Ref. No: 2400/2025	

To All Members,

Sub: Revocation of suspension of trading in equity shares of Vivimed Labs Limited

Pursuant to the provisions of SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 ("Master Circular") (Erstwhile SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023), trading in securities of Vivimed Labs Limited ('the Company') was suspended with effect from January 19, 2023 on account of non-compliance with Regulation 34 of SEBI (LODR) Regulations, 2015 for the financial year ended March 31, 2021 and March 31, 2022.

It is hereby notified that the suspension in trading of equity shares of **Vivimed Labs Limited** will be revoked w.e.f. December 18, 2025 as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 ("Master Circular") (Erstwhile SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023). Details are as under: -

Symbol	VIVIMEDLAB
Company Name	Vivimed Labs Limited
Series	BE
ISIN	INE526G01021
Face value (in Rs.)	2
Reason for Revocation	The Company has applied for Revocation of Suspension and has complied with SEBI (LODR) Regulations, 2015
Issued capital (No. of shares)	8,29,13,915

Note: The trade in aforesaid securities will be executed in 'BE' series and will be settled on trade for trade basis.

Members are requested to note that the above security will be part of special pre-open session on December 18, 2025 as per SEBI circular no. CIR/MRD/DP/01/2012 & CIR/MRD/DP/02/2012 dated January 20, 2012.

The circular shall be effective from December 18, 2025.

For and on behalf of
For National Stock Exchange of India Limited

Aseem Sehgal
Senior Manager